ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 128 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q3 2020. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $120,379,132 | -12.2% | 4,711,512 | -1.4% | 0.32% | -5.6% |
Q2 2023 | $137,047,380 | +19.6% | 4,778,500 | 0.0% | 0.34% | +18.1% |
Q1 2023 | $114,540,645 | +59.3% | 4,778,500 | +12.7% | 0.29% | +44.7% |
Q4 2022 | $71,902,836 | +36.0% | 4,239,554 | +18.8% | 0.20% | +28.4% |
Q3 2022 | $52,870,000 | -5.7% | 3,567,497 | +0.2% | 0.16% | +2.0% |
Q2 2022 | $56,052,000 | -44.7% | 3,561,097 | -5.3% | 0.15% | -33.6% |
Q1 2022 | $101,421,000 | -25.8% | 3,761,900 | +1.8% | 0.23% | -9.8% |
Q4 2021 | $136,749,000 | -6.0% | 3,694,929 | +21.3% | 0.25% | -8.3% |
Q3 2021 | $145,504,000 | +42.0% | 3,045,288 | +0.6% | 0.28% | +45.0% |
Q2 2021 | $102,468,000 | -22.5% | 3,028,000 | -5.5% | 0.19% | -25.7% |
Q1 2021 | $132,284,000 | -11.7% | 3,203,000 | -7.2% | 0.26% | -16.0% |
Q4 2020 | $149,783,000 | +153.6% | 3,452,810 | +150.8% | 0.31% | +121.7% |
Q3 2020 | $59,060,000 | +105.4% | 1,376,675 | +123.8% | 0.14% | +94.4% |
Q2 2020 | $28,747,000 | – | 615,044 | – | 0.07% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DFPG INVESTMENTS, LLC | 183,803 | $9,359,000 | 5.00% |
DAFNA Capital Management LLC | 229,652 | $9,852,000 | 3.20% |
HealthCor Management, L.P. | 1,594,452 | $68,402,000 | 2.74% |
Capital Impact Advisors, LLC | 110,000 | $4,719,000 | 1.40% |
Cormorant Asset Management, LP | 700,000 | $30,030,000 | 1.16% |
ARK Investment Management | 2,495,842 | $107,072,000 | 0.64% |
Millrace Asset Group, Inc. | 18,087 | $776,000 | 0.63% |
COOPER CREEK PARTNERS MANAGEMENT LLC | 50,532 | $2,168,000 | 0.54% |
Endurant Capital Management LP | 34,485 | $1,479,000 | 0.44% |
HealthCor Management, L.P. | 200,000 | $8,580,000 | 0.34% |